← Leaderboards
Robert Damoiseaux
University Of California Los Angeles
$5,020,054
Attributed
$7,371,401
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,371,401 · 7
By mechanism
U01$2,367,083 · 1
S10$1,869,146 · 1
P30$1,588,588 · 3
R01$1,113,459 · 1
R21$433,125 · 1
Top collaborators
- Brigitte N Gomperts7 shared
- John A Belperio4 shared
- Otto O Yang1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Andre Elias Nel$21,296,649
- Zoran Galic$3,509,989
- David T Wong$54,826,713
- Xiaofeng Zhou$2,882,296
- Anh D Le$4,956,118
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeMolecularDrug DiscoveryPhenotypeCellsCell LineHigh Throughput ScreeningResearch PersonnelPharmaceutical PreparationsResource SharingScreeningDrug DevelopmentResourcesClinical TrialsFunctional GenomicsInternationalReporterSuccessSmall Hairpin RnaLibrariesComplementary DnaSamplingClinicPrevent
Grant awards (15)
Automated Cell Culture System$1,869,146
S10 · FY2025 · OD · contact PI
Small Molecule Inhibitors Against HPV-Induced Orophageal Cancers$433,125
R21 · FY2025 · DE
Molecular Screening Shared Resource (MSSR)$217,052
P30 · FY2025 · CA · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$617,814
U01 · FY2024 · HL
Molecular Screening Shared Resource (MSSR)$274,605
P30 · FY2024 · CA · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$630,424
U01 · FY2023 · HL
Molecular Screening Shared Resource (MSSR)$274,598
P30 · FY2023 · CA · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$630,424
U01 · FY2022 · HL
Molecular Screening Shared Resource (MSSR)$274,598
P30 · FY2022 · CA · contact PI
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis$488,421
U01 · FY2021 · HL
Molecular Screening Shared Resource (MSSR)$274,598
P30 · FY2021 · CA · contact PI
Molecular Screening Shared Resource (MSSR)$273,137
P30 · FY2020 · CA · contact PI
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$374,274
R01 · FY2017 · GM
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$405,875
R01 · FY2016 · GM
Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary Fibrosis$333,310
R01 · FY2015 · GM